UB Paderborn / Katalog / Suche / in CDI

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

PloS one, 2022-07, Vol.17 (7), p.e0268244-e0268244

2022

Link zum Volltext

Verfügbarkeit prüfen

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell reports (Cambridge), 2018-03, Vol.22 (11), p.2978-2994

2018

Link zum Volltext

Verfügbarkeit prüfen

Modulation of GITR for cancer immunotherapy

Current opinion in immunology, 2012-04, Vol.24 (2), p.217-224

2012

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Clinical cancer research, 2013-03, Vol.19 (5), p.1009-1020

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.47-47, Article 47

2018

Link zum Volltext

Verfügbarkeit prüfen

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

PloS one, 2010-05, Vol.5 (5), p.e10436-e10436

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

Journal for Immunotherapy of Cancer, 2014-04, Vol.2 (1), p.7-7

2014

Link zum Volltext

Verfügbarkeit prüfen

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Clinical cancer research, 2019-12, Vol.25 (23), p.7175-7188

2019

Link zum Volltext

Verfügbarkeit prüfen

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

Science signaling, 2017-08, Vol.10 (494)

2017

Link zum Volltext

Verfügbarkeit prüfen

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

PloS one, 2011-06, Vol.6 (6), p.e21214-e21214

2011

Link zum Volltext

Verfügbarkeit prüfen

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability

Cancer immunology research, 2013-11, Vol.1 (5), p.320-331

2013

Link zum Volltext

Verfügbarkeit prüfen

Hiding the road signs that lead to tumor immunity

The Journal of experimental medicine, 2011-09, Vol.208 (10), p.1937-1940

2011

Link zum Volltext

Verfügbarkeit prüfen

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

mAbs, 2018-08, Vol.10 (6), p.913-921

2018

Link zum Volltext

Verfügbarkeit prüfen

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy

Current opinion in investigational drugs (London, England : 2000), 2010-12, Vol.11 (12), p.1378

2010

Link zum Volltext

Verfügbarkeit prüfen

Calcitonin Gene-Related Peptide Decreases Expression of HLA-DR and CD86 by Human Dendritic Cells and Dampens Dendritic Cell-Driven T Cell-Proliferative Responses Via the Type I Calcitonin Gene-Related Peptide Receptor

The Journal of immunology (1950), 2000-04, Vol.164 (7), p.3494-3499

2000

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3017-3017

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3632-3632

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3945-3945

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.583-583

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT018-CT018

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeting the TGF[beta] pathway with galunisertib, a TGF[beta]RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1)

2018

Link zum Volltext

Verfügbarkeit prüfen

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3003-3003

2013

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.O6-O6, Article O6

2013

Link zum Volltext

Verfügbarkeit prüfen

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

mAbs, 2018, Vol.10 (6), p.913-921

2018

Link zum Volltext

Verfügbarkeit prüfen

Haptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis

American journal of respiratory and critical care medicine, 2016-05, Vol.193 (10), p.1111-1122

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Modulation of GITR for cancer immunotherapy

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability

Hiding the road signs that lead to tumor immunity

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy

Calcitonin Gene-Related Peptide Decreases Expression of HLA-DR and CD86 by Human Dendritic Cells and Dampens Dendritic Cell-Driven T Cell-Proliferative Responses Via the Type I Calcitonin Gene-Related Peptide Receptor

First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial

Targeting the TGF[beta] pathway with galunisertib, a TGF[beta]RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Haptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis

Suchergebnisse filtern